Search Results | Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Abstract B05: Mechanisms of PPM1D-mediated tumorigenesis in diffuse intrinsic pontine glioma (DIPG)

Mwangala P. Akamandisa, Kai Nie, Jing Wen, Rita Nahta, Dolores Hambardzumyan, Robert C. Castellino

Cancer Res (2018) 78 (19_Supplement): B05.

DOI: https://doi.org/10.1158/1538-7445.PEDCA17-B05

Published: 01 October 2018

View article

Journal Articles

Abstract 889: Growth differentiation factor 15 causes increased invasiveness and EMT in HER2-overexpressing breast cancer via activation of p38 MAPK.

Jayashree P. Joshi, Zhengjia Chen, Rita Nahta

Cancer Res (2013) 73 (8_Supplement): 889.

DOI: https://doi.org/10.1158/1538-7445.AM2013-889

Published: 15 April 2013

View article

Journal Articles

Abstract P4-07-02: Growth differentiation factor 15, a novel mediator of progression in HER2-positive breast cancer

Rita Nahta, Jayashree P Joshi, Samantha E Griner, Amy L Adams, Fabrice Andre

Cancer Res (2012) 72 (24_Supplement): P4-07-02.

DOI: https://doi.org/10.1158/0008-5472.SABCS12-P4-07-02

Published: 15 December 2012

View article

Journal Articles

Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer

Ruth M. O'Regan, Sheryl Gabram, Toncred Styblo, Monica Rizzo, William Wood, Jayanthi Srinivasiah, William Jonas, Fred Schnell, Amy Adams, Rita Nahta, Amelia Zelnak

Cancer Res (2012) 72 (8_Supplement): 2703.

DOI: https://doi.org/10.1158/1538-7445.AM2012-2703

Published: 15 April 2012

View article

Journal Articles

Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism

Yuhua Zhao, Hao Liu, Zixing Liu, Yan Ding, Susan P. LeDoux, Glenn L. Wilson, Richard Voellmy, Yifeng Lin, Wensheng Lin, Rita Nahta, Bolin Liu, Oystein Fodstad, Jieqing Chen, Yun Wu, Janet E. Price, Ming Tan

Cancer Res (2011) 71 (13): 4585–4597.

DOI: https://doi.org/10.1158/0008-5472.CAN-11-0127

Published: 30 June 2011

View article

Includes: Supplementary data

Journal Articles

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma.

Hiroaki Itamochi, Junzo Kigawa, Yasunobu Kanamori, Tetsuro Oishi, Chandra Bartholomeusz, Rita Nahta, Francisco J. Esteva, Nour Sneige, Naoki Terakawa, Naoto T. Ueno

Cancer Res (2006) 66 (8_Supplement): 1289–1290.

Published: 15 April 2006

View article

Journal Articles

The dual EGFR/HER-2 kinase inhibitor lapatinib induces apoptosis and potentiates anti-IGF-IR therapy in trastuzumab-resistant breast cancer cells

Rita Nahta, Linda Xh Yuan, Francisco J. Esteva

Cancer Res (2006) 66 (8_Supplement): 1116.

Published: 15 April 2006

View article

Journal Articles

Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells

Rita Nahta, Linda X.H. Yuan, Bing Zhang, Ryuji Kobayashi, Francisco J. Esteva

Cancer Res (2005) 65 (23): 11118–11128.

DOI: https://doi.org/10.1158/0008-5472.CAN-04-3841

Published: 01 December 2005

View article

Journal Articles

P27^kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

Rita Nahta, Takeshi Takahashi, Naoto T. Ueno, Mien-Chie Hung, Francisco J. Esteva

Cancer Res (2004) 64 (11): 3981–3986.

DOI: https://doi.org/10.1158/0008-5472.CAN-03-3900

Published: 01 June 2004

View article

Journal Articles

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Rita Nahta, Mien-Chie Hung, Francisco J. Esteva

Cancer Res (2004) 64 (7): 2343–2346.

DOI: https://doi.org/10.1158/0008-5472.CAN-03-3856

Published: 01 April 2004

View article

Journal Articles

Epidermal Growth Factor Receptor Expression Is a Candidate Target of the Synergistic Combination of Trastuzumab and Flavopiridol in Breast Cancer

Rita Nahta, Sally Trent, Chuanwei Yang, Emmett V. Schmidt

Cancer Res (2003) 63 (13): 3626–3631.

Published: 01 July 2003

View article

Journal Articles

Rate-limiting Effects of Cyclin D1 in Transformation by ErbB2 Predicts Synergy between Herceptin and Flavopiridol

Rita Nahta, J. Dirk Iglehart, Bettina Kempkes, Emmett V. Schmidt

Cancer Res (2002) 62 (8): 2267–2271.

Published: 01 April 2002

View article

NARROW

Abstract B05: Mechanisms of PPM1D-mediated tumorigenesis in diffuse intrinsic pontine glioma (DIPG)

Abstract 889: Growth differentiation factor 15 causes increased invasiveness and EMT in HER2-overexpressing breast cancer via activation of p38 MAPK.

Abstract P4-07-02: Growth differentiation factor 15, a novel mediator of progression in HER2-positive breast cancer

Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer

Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma.

The dual EGFR/HER-2 kinase inhibitor lapatinib induces apoptosis and potentiates anti-IGF-IR therapy in trastuzumab-resistant breast cancer cells

Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells

P27^kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Epidermal Growth Factor Receptor Expression Is a Candidate Target of the Synergistic Combination of Trastuzumab and Flavopiridol in Breast Cancer

Rate-limiting Effects of Cyclin D1 in Transformation by ErbB2 Predicts Synergy between Herceptin and Flavopiridol

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only